Jae Park, MD
Memorial Sloan Kettering Cancer Center
17
17
2
N/A
0
14
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+24 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (17)
Showing 10 of 17 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Worked with same sponsors:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Helen Heslop, MD
Baylor College of Medicine
Shared therapeutic areas:
Worked with same sponsors:
Brigitte C Widemann, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Qifa Liu
Nanfang Hospital, Southern Medical University
Shared therapeutic areas:
Arnon Nagler, MD
Chaim Sheba Medical Center
Shared therapeutic areas:
Yves Beguin, MD, PhD
CHU-ULg
Shared therapeutic areas:
Worked with same sponsors:
David Avigan, MD
Beth Israel Deaconess Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Guillermo Garcia-Manero, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (17)
Showing 17 of 17 trials
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
All 17 trials loaded